Drug Pricing Reform As Legislative ‘Pay For’ Gaining Momentum But What About Part D Redesign?
Executive Summary
Association for Accessible Medicines makes a case for lowering prices in Part D through benefit design reforms enabling quicker and better access to first generics.
You may also be interested in...
Part D Cost Sharing Cap May Have Broadest Benefit For Jakafi, Revlimid, Pomalyst, Imbruvica Users
A cap set at $2,000 would help nearly 1 million more seniors than a cap set at $3,100, according to new study by Kaiser Family Foundation. Either competing legislative proposal would probably be welcomed by pharma industry as way to defuse pricing debate.
Generics Coverage In Medicare Part D Plans Worsens In 2021
Generic prescription drugs are only placed on generic tiers 45% of the time in 2021, a significant decrease from the 64% seen in 2016, according to the latest AAM-sponsored study by Avalere Health. AAM is urging policymakers to initiate Medicare Part D reforms.
Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.